- Home
- TRNO vs RYTM Comparison
TRNO vs RYTM Comparison
Compare TRNO & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRNO | RYTM |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.4B |
| IPO Year | 2010 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TRNO | RYTM |
|---|---|---|
| Price | $65.05 | $103.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $65.58 | ★ $129.92 |
| AVG Volume (30 Days) | ★ 821.9K | 590.7K |
| Earning Date | 02-05-2026 | 02-25-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | ★ 103.65 | N/A |
| EPS | ★ 3.91 | N/A |
| Revenue | ★ $476,383,000.00 | $174,334,000.00 |
| Revenue This Year | $23.60 | $47.98 |
| Revenue Next Year | $7.96 | $56.07 |
| P/E Ratio | $16.48 | ★ N/A |
| Revenue Growth | 24.50 | ★ 54.92 |
| 52 Week Low | $48.18 | $45.91 |
| 52 Week High | $69.20 | $122.20 |
Technical Indicators
Market Signals| Indicator | TRNO | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 68.37 | 47.03 |
| Support Level | $59.82 | $100.59 |
| Resistance Level | $61.97 | $111.25 |
| Average True Range (ATR) | 1.36 | 5.03 |
| MACD | 0.36 | 0.28 |
| Stochastic Oscillator | 95.27 | 35.15 |
Price Performance
Historical ComparisonAbout TRNO Terreno Realty Corporation
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.